Deals

News Photos

Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial
Click on the image below to view in Stereo 3D

Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19
Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The U.S. government will accept the vials of bamlanivimab if it is granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). Lilly submitted a request for an EUA for bamlanivimab for the treatment of mild to moderate COVID-19 in high-risk patients to the FDA in early October. The initial agreement is for delivery over the two months following an EUA and also provides the option for the U.S. government to purchase up to an additional 650,000 vials through June 30, 2021, under the same terms as the base agreement and subject to agreement from Lilly, product availability and the medical need in the U.S.
More Description
Image URL


Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment
Nearly 80% of people taking calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) for the preventive treatment of migraine reported their migraine as "better" overall since starting their medication, according to a web-based population survey. Close to two-thirds (62.6%) said they also used an additional recommended migraine preventive medication with their CGRP mAbs. Eli Lilly and Company (NYSE: LLY) announced today the results, which are among the first real-world, population-based, patient-reported outcomes from people using CGRP mAbs as a migraine preventive treatment and suggest these novel medications lead to improvement in how patients perceive their migraine. The latest findings from Lilly's OVERCOME study are being presented virtually at the 18th Migraine Trust International Symposium (MTIS 2020).
More Description
Image URL


Indy Racial Equity Pledge Launches to Drive Accountability, Action and Progress on Racial Equity
A local coalition of corporate and civic organizations has launched the Indy Racial Equity Pledge to hold their organizations accountable for driving measurable progress in advancing racial equity for African Americans in Central Indiana. By signing the pledge, organizations commit to use their resources and influence to accelerate progress on racial equity in four key areas: health, prosperity, education and criminal justice.
More Description
Image URL


Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries
Eli Lilly and Company (NYSE: LLY) and the Bill & Melinda Gates Foundation, as part of the COVID-19 Therapeutics Accelerator, have entered into an agreement to facilitate access to future Lilly therapeutic antibodies under development for the prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus, to benefit low- and middle-income countries. Therapeutic antibodies have the potential to prevent and treat COVID-19, reducing the burden on healthcare systems worldwide. This effort to bring equitable access to novel treatments is part of the COVID-19 Therapeutics Accelerator, an initiative launched by the Gates Foundation, Wellcome, and Mastercard to speed the development of and access to therapies for COVID-19.
More Description
Image URL


Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial
Eli Lilly and Company (NYSE:LLY) announced today new efficacy and safety data from the Phase 2 SERENITY study evaluating mirikizumab in patients with moderately to severely active Crohn's disease, a form of inflammatory bowel disease (IBD) that can cause systemic inflammation manifested as abdominal pain, diarrhea, fever, weight loss and lead to intestinal obstruction, fibrosis and other complications. SERENITY included a 12-week induction period and 40-week continued treatment period, which evaluated the safety and efficacy of multiple dosing regimens and two methods of administration through Week 52 as measured by endoscopic response, which reflects substantial reduction in inflammation of the lining of the bowel as seen during an endoscopy, and by Patient Reported Outcomes (PRO) remission, two important treatment goals in Crohn's disease. Detailed results from the trial are being presented virtually today in an abstract session at the United European Gastroenterology Week (UEG Week) 2020.
More Description
Image URL

 
 
 
vlrPhone
vlrFilter
vlrMemos

Project of very low consumption, radiation and bitrate softphones
Multifunction Audio Filter with Remote Control
App to measure the quality of the voice
More Information
Free the Animation VR
AR

Play to reveal 3D images and 3D models
More Information

WhmSoft Moblog
Copyright (C) 2006-2021 WhmSoft
All Rights Reserved